Online inquiry

IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8338MR)

This product GTTS-WQ8338MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Glioblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001128148.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7037
UniProt ID P02786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8338MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7479MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ9262MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8934MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ15328MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ11410MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ5659MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ11637MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ12115MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW